Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2008, Vol. 35 Issue (3): 208-210    DOI:
Original Research Previous articles | Next articles
Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome
P. Gkogkos1, G. Androutsopoulos1, *(), P. Vassilakos2, G. Panayiotakis3, G. Kourounis1, G. Decavalas1
1Department of Obstetrics and Gynaecology, University of Patras, Medical School, Rion
2Department of Nuclear Medicine, University of Patras, Medical School, Rion
3Department of Medical Physics, University of Patras, Medical School, Rion (Greece)
Download:  PDF(60KB)  ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: In this prospective study, we investigated the association between mid-trimester maternal serum alpha-fetoprotein AFP (MSAFP) levels and adverse pregnancy outcome in a South-Western Greek population. Materials and Methods: 110 healthy Greek women with spontaneous pregnancies, investigated for MSAFP levels between the 13th and 24th week of gestation and followed for adverse pregnancy outcome. AFP levels > 2.0 multiples of the median value for gestation were considered abnormal. Statistical analysis was performed by Pearson’s chi-square test. Results: Elevated MSAFP levels were detected in a total of 27 of the 110 women studied (24.5%). Among them, only four women (14.8%) developed pregnancy complications. Conclusion: Multiparameter testing of placental function in the mid-trimester (uterine artery Doppler, placental morphology and MSAFP screening) may allow us to identify women with increased risk of developing severe placental insufficiency and pregnancy complications.
Key words:  Maternal serum AFP levels      Adverse pregnancy outcome     
Published:  10 September 2008     
*Corresponding Author(s):  G. ANDROUTSOPOULOS     E-mail:  androutsopoulosgeorgios@hotmail.com

Cite this article: 

P. Gkogkos, G. Androutsopoulos, P. Vassilakos, G. Panayiotakis, G. Kourounis, G. Decavalas. Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome. Clinical and Experimental Obstetrics & Gynecology, 2008, 35(3): 208-210.

URL: 

https://ceog.imrpress.com/EN/     OR     https://ceog.imrpress.com/EN/Y2008/V35/I3/208

[1] C. Chollet, B. Andre, M. Voglimacci, A. Ghassani, O. Parant, P. Guerby. Perinatal outcomes of second trimester antenatal genital bleeding[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 105-110.
[2] G. Aksan Desteli, N. Şahin-Uysal, T. Çok, Ç. Gülümser, H. Kalaycı, F. F. Yanık. First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(5): 673-677.
[3] G. Androutsopoulos, P. Gkogkos, V. Papadopoulos, G. Adonakis, V. Tsapanos,P. Vassilakos, G. Panayiotakis, G. Decavalas. Mid-trimester maternal serum markers in predicting adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2009, 36(4): 237-240.
[4] G. Androutsopoulos, P. Gkogkos, P. Vassilakos, G. Panayiotakis, G. Decavalas. Mid-trimester maternal serum hCG levels in predicting adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2009, 36(3): 173-175.
[5] R. Axt-Fliedner. Second trimester uterine artery Doppler ultrasound as a screening test for adverse pregnancy outcome[J]. Clinical and Experimental Obstetrics & Gynecology, 2004, 31(1): 9-11.
No Suggested Reading articles found!